Company performance
Current Price
as of Jan 17, 2025$1.50
P/E Ratio
N/A
Market Cap
$44.38M
- PVT
Description
Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.
Metrics
Overview
- HQJupiter, FL
- SectorHealth Services
- IndustryMedical/Nursing Services
- TickerDYAI
- Price$1.5+0.67%
Trading Information
- Market cap$44.38M
- Float68.81%
- Average Daily Volume (1m)167,803
- Average Daily Volume (3m)102,238
- EPS-$0.22
Company
- Revenue$3.36M
- Rev growth (1yr)393.00%
- Net income-$0.20M
- Gross margin79.78%
- EBITDA margin-10.04%
- EBITDA-$0.20M
- EV$26.13M
- EV/Revenue7.77
- P/EN/A
- P/S13.15
- P/B13.01
Documents
SEC Filings
Factset Street Account
Dyadic International reports Q3 EPS ($0.06) vs year-ago ($0.06) ($1.70, 0.00) (2023-11-08T21:01:09Z)
Earnings Calls
Factset